<DOC>
	<DOCNO>NCT00898547</DOCNO>
	<brief_summary>RATIONALE : Collecting store sample blood patient cancer study laboratory may help doctor learn cancer identify biomarkers related cancer . PURPOSE : This laboratory study look biomarkers angiogenesis disease patient unresectable malignant mesothelioma treat clinical trial CALGB-30107 .</brief_summary>
	<brief_title>Biomarkers Angiogenesis Disease Patients With Unresectable Malignant Mesothelioma Treated Clinical Trial CALGB-30107</brief_title>
	<detailed_description>OBJECTIVES : - Determine elevate level thrombospondin I serum level , vascular endothelial growth factor receptor I , fibroblast growth factor , transform growth factor , mesothelin portend poor prognosis patient unresectable malignant mesothelioma treat vatalanib protocol CALGB-30107 . - Determine elevate level thrombospondin I serum level , vascular endothelial growth factor receptor I , fibroblast growth factor , transform growth factor , mesothelin correlate response stable disease patient . OUTLINE : Serum sample previously obtain patient protocol CALGB-30107 test level thrombospondin I serum , vascular endothelial growth factor receptor I , fibroblast growth factor , transform growth factor , mesothelin use enzyme-linked immunosorbent assay ( ELISA ) . PROJECTED ACCRUAL : A total 47 specimen accrue study .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis malignant mesothelioma Unresectable disease Must receive treatment vatalanib protocol CALGB30107 PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
	<keyword>epithelial mesothelioma</keyword>
	<keyword>sarcomatous mesothelioma</keyword>
</DOC>